The US Department of Health and Human Services (HHS) is boosting capacity to produce recombinant influenza vaccine in the USA.
The HHS said it was issuing a six-year, $226 million contract to fund a public-private partnership between the Biomedical Advanced Research and Development Authority (BARDA) and French drugmaker Sanofi (Euronext: SAN).
Sanofi will retrofit vaccine manufacturing facilities in Swiftwater, Pennsylvania, doubling its US-based recombinant protein-based flu vaccine manufacturing capacity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze